GT Biopharma reports Q3 EPS (6c) vs. (22c) last year

“We continue to move forward in advancing our novel portfolio of TriKE nanobody assets,” said Michael Breen, Executive Chairman and interim Chief Executive Office of GT Biopharma. “We remain on track to submit an IND to the U.S. Food and Drug Administration in Q4 2023 for GTB-3650, a second generation nanobody TriKE for the treatment of CD33+ leukemia. Following FDA acceptance, we plan to host a KOL event highlighting the anticipated Phase 1 clinical trial design and timelines for data. Our current cash runway is sufficient to progress through multiple upcoming milestones in 2024, and we continue to actively explore potential development partnerships for our programs.”